WINTON GROUP Ltd Reduces Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

WINTON GROUP Ltd lowered its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) by 29.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 92,235 shares of the company’s stock after selling 38,730 shares during the quarter. WINTON GROUP Ltd’s holdings in Vir Biotechnology were worth $677,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. purchased a new position in shares of Vir Biotechnology during the 4th quarter worth approximately $60,000. PNC Financial Services Group Inc. boosted its position in shares of Vir Biotechnology by 31.8% during the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,999 shares in the last quarter. KBC Group NV grew its stake in Vir Biotechnology by 136.5% in the fourth quarter. KBC Group NV now owns 8,970 shares of the company’s stock worth $66,000 after purchasing an additional 5,177 shares during the period. CIBC Asset Management Inc bought a new position in Vir Biotechnology in the fourth quarter worth $74,000. Finally, Virtu Financial LLC purchased a new position in Vir Biotechnology during the fourth quarter valued at $94,000. 65.32% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on VIR shares. Leerink Partners upped their target price on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, February 28th. JPMorgan Chase & Co. boosted their price target on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research report on Thursday, January 9th. Barclays raised their price objective on Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Finally, Morgan Stanley raised Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $35.67.

Vir Biotechnology Stock Up 0.4 %

Shares of NASDAQ VIR opened at $6.70 on Friday. The company has a 50 day moving average of $8.80 and a 200 day moving average of $8.35. Vir Biotechnology, Inc. has a twelve month low of $6.40 and a twelve month high of $14.45. The firm has a market cap of $918.86 million, a P/E ratio of -1.71 and a beta of 1.17.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $12.37 million for the quarter, compared to the consensus estimate of $8.14 million. As a group, equities analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Insider Buying and Selling at Vir Biotechnology

In other news, Director Vicki L. Sato sold 10,960 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total transaction of $137,219.20. Following the completion of the transaction, the director now directly owns 1,312,391 shares of the company’s stock, valued at $16,431,135.32. The trade was a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director George A. Scangos sold 10,964 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the completion of the sale, the director now owns 708,295 shares in the company, valued at $6,948,373.95. This represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,859 shares of company stock worth $326,458. Company insiders own 15.60% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).